Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMD (NASDAQ:CPIX)
· seekingalpha.com
Cumberland Pharmaceuticals reports $77.8 million Q3 net income and $80.6 million in cash with no debt.
Earnings Call Insights Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMD Nov 10, 2026, 6:4...